GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » ROA %

Mega Genomics (HKSE:06667) ROA % : -1.33% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Mega Genomics's annualized Net Income for the quarter that ended in Dec. 2023 was HK$-11.1 Mil. Mega Genomics's average Total Assets over the quarter that ended in Dec. 2023 was HK$837.7 Mil. Therefore, Mega Genomics's annualized ROA % for the quarter that ended in Dec. 2023 was -1.33%.

The historical rank and industry rank for Mega Genomics's ROA % or its related term are showing as below:

HKSE:06667' s ROA % Range Over the Past 10 Years
Min: -2.27   Med: 11.26   Max: 22.56
Current: 4

During the past 5 years, Mega Genomics's highest ROA % was 22.56%. The lowest was -2.27%. And the median was 11.26%.

HKSE:06667's ROA % is ranked better than
73.59% of 231 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.92 vs HKSE:06667: 4.00

Mega Genomics ROA % Historical Data

The historical data trend for Mega Genomics's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics ROA % Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
11.26 22.56 13.05 -2.27 3.96

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROA % Get a 7-Day Free Trial 11.32 4.58 -9.51 9.65 -1.33

Competitive Comparison of Mega Genomics's ROA %

For the Diagnostics & Research subindustry, Mega Genomics's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mega Genomics's ROA % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's ROA % distribution charts can be found below:

* The bar in red indicates where Mega Genomics's ROA % falls into.



Mega Genomics ROA % Calculation

Mega Genomics's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=32.855/( (788.064+871.241)/ 2 )
=32.855/829.6525
=3.96 %

Mega Genomics's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-11.11/( (804.121+871.241)/ 2 )
=-11.11/837.681
=-1.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Mega Genomics  (HKSE:06667) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-11.11/837.681
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-11.11 / 114.674)*(114.674 / 837.681)
=Net Margin %*Asset Turnover
=-9.69 %*0.1369
=-1.33 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Mega Genomics ROA % Related Terms

Thank you for viewing the detailed overview of Mega Genomics's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Genomics (HKSE:06667) Business Description

Traded in Other Exchanges
N/A
Address
North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening and infectious disease diagnosis, to meet consumers' growing preventive medical needs.
Executives
Guo Meiling 2101 Beneficial owner
Lin Lin 2101 Beneficial owner
Yu Rong 2501 Other
Infinite Galaxy Health Limited 2101 Beneficial owner
Mei Nian Investment Limited 2101 Beneficial owner
Kastle Limited 2501 Other
Mega Marvelous Limited 2501 Other
Yurong Technology Limited 2101 Beneficial owner
Niu Zhencai 2201 Interest of corporation controlled by you
Mei Nian Da Jian Kang Chan Ye Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si 2501 Other
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

Mega Genomics (HKSE:06667) Headlines

No Headlines